CD19 and B-cell chronic lymphocytic leukemia: suggested that a BiKE binding CD16 and CD19 and a TriKE binding CD16, CD19 and CD22 enhanced the NK cell cytotoxicity and production of IFNγ, which increased the efficacy of NK cells in killing CLL cells consequently (136).